Incidence of lymphomas in inflammatory bowel disease: report of an emblematic case, systematic review, and meta-analysis.
| العنوان: | Incidence of lymphomas in inflammatory bowel disease: report of an emblematic case, systematic review, and meta-analysis. |
|---|---|
| المؤلفون: | Russo MF; Department of Surgery, Sapienza University of Rome, Rome, Italy., Diddoro A; Department of Surgery, Sapienza University of Rome, Rome, Italy., Iodice A; Department of Surgery, Sapienza University of Rome, Rome, Italy., Severi C; Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy., Castagneto-Gissey L; Department of Surgery, Sapienza University of Rome, Rome, Italy., Casella G; Department of Surgery, Sapienza University of Rome, Rome, Italy. |
| المصدر: | Frontiers in medicine [Front Med (Lausanne)] 2023 May 03; Vol. 10, pp. 1172634. Date of Electronic Publication: 2023 May 03 (Print Publication: 2023). |
| نوع المنشور: | Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne, Switzerland : Frontiers Media S.A., [2014]- |
| مستخلص: | Introduction: Over the past 20 years, the increasing use of combined therapy with immunosuppressants and biologic agents has markedly reduced the use of steroids in the management of inflammatory bowel diseases (IBD). However, medical therapy seems to promote, in the long run, carcinogenesis resulting in an increased risk of developing different types of malignancies, including lymphomas. The aim of this study was to systematically review the current incidence and prognosis of lymphoid neoplasms occurring in patients with IBD. Methods: Studies analyzing the incidence of lymphomas in subjects of age >18 years affected by IBD were included in this systematic review and meta-analysis. Studies focusing on pediatric populations, not reporting person-years of follow-up, or with a duration < 1 year were excluded. PubMed, Embase, Web of Science Core Collection, and Cochrane Central Register were searched from inception through January 2022. Publication bias within studies was assessed using Begg's and Egger's tests and random effects model. Quantitative results were synthesized using relative-risk meta-analysis. PRISMA guidelines were used to carry out this systematic review (PROSPERO Registration Number: CRD42023398348). Results: A total of 345 studies published between 1985 and 2022, with a total of 6,17,386 patients were included in the meta-analysis. Substantial heterogeneity between studies prevented the pooling of estimates ( I 2 = 97.19%). Evidence of publication bias was overall low ( p = 0.1941). Patients affected by Crohn's disease (CD) were 1,86,074 (30.13%), while 2,78,876 (46.17%) were diagnosed with UC. The remaining 23.7% of cases were diagnosed with indeterminate colitis. Immunomodulators and biologic therapy were used in 24,520 (5.27%), and 17,972 (3.86%) patients, respectively. Reported incidence rates for lymphoma in IBD ranged from 0.0/100,000 person/years (py) (95% CI 0.0-3.7/100,000) to 89/100,000 py (95% CI 36-160/100,000). Reported incidence rates of lymphoma in CD ranged from 0.0/100,000 py (95% CI 0.0-3.7/100,000) to 91/100,000 py (95% CI 18-164/100,000). For UC, the incidence rate ranged from 0.0/100,000 py (95% CI 0.0-3.7/100,000) to 95/100,000 py (95% CI 0-226/100,000). Male-to-female ratio was ~4:1. Therapy with immunomodulators was directly associated with an increased incidence of lymphoma ( p < 0.0001). Evidence of publication bias was overall low ( p = 0 .1941). Conclusions: The evidence arising from this study highlights a correlation between the use of immunomodulators and subsequent lymphoma development. Combined multidisciplinary approach and long-term follow-up are warranted in order to decrease mortality deriving from the coexistence of both conditions. Systematic Review Registration: Identifier: CRD42023398348. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Russo, Diddoro, Iodice, Severi, Castagneto-Gissey and Casella.) |
| References: | Digestion. 2010;81(4):265-70. (PMID: 20134166) Br Dent J. 2003 Jan 25;194(2):73-8. (PMID: 12577072) Gastroenterology. 2001 Nov;121(5):1080-7. (PMID: 11677199) Gastroenterol Hepatol. 2010 Jan;33(1):12-6. (PMID: 19889478) Front Pharmacol. 2019 Mar 19;10:247. (PMID: 30941038) Am J Epidemiol. 2013 Jun 1;177(11):1296-305. (PMID: 23514635) BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) Inflamm Bowel Dis. 2015 Aug;21(8):1847-53. (PMID: 25993693) Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833) Mutat Res. 2001 Sep 1;480-481:129-38. (PMID: 11506806) Stat Med. 2002 Jun 15;21(11):1539-58. (PMID: 12111919) Dig Liver Dis. 2016 Oct;48(10):1162-7. (PMID: 27481588) Drugs Aging. 2017 Nov;34(11):859-868. (PMID: 29170864) Inflamm Bowel Dis. 2020 Aug 20;26(9):1330-1339. (PMID: 32322878) Aliment Pharmacol Ther. 2018 Oct;48(7):723-730. (PMID: 30095176) J Gastroenterol Hepatol. 2013 Aug;28(8):1300-5. (PMID: 23488881) J Crohns Colitis. 2016 Aug;10(8):913-24. (PMID: 26933032) J Crohns Colitis. 2017 Jun 01;11(6):680-689. (PMID: 28025307) Lancet. 1991 Nov 9;338(8776):1175-6. (PMID: 1682595) Am J Gastroenterol. 2013 Dec;108(12):1869-76. (PMID: 23978954) J Autoimmun. 2017 Jun;80:56-64. (PMID: 28214146) Blood. 2012 Jan 19;119(3):651-65. (PMID: 22053109) Inflamm Bowel Dis. 2020 Feb 11;26(3):450-459. (PMID: 31498388) Am J Gastroenterol. 2019 Jan;114(1):116-126. (PMID: 30333538) Scand J Gastroenterol. 2013 Dec;48(12):1405-13. (PMID: 24131389) Lancet. 2009 Nov 7;374(9701):1617-25. (PMID: 19837455) Lancet. 1988 Dec 10;2(8624):1323-7. (PMID: 2904050) Gastroenterology. 1999 Dec;117(6):1433-7. (PMID: 10579985) Clin Gastroenterol Hepatol. 2009 Aug;7(8):874-81. (PMID: 19558997) Gastroenterology. 2014 Apr;146(4):941-9. (PMID: 24361468) Clin Gastroenterol Hepatol. 2004 Dec;2(12):1088-95. (PMID: 15625654) J Crohns Colitis. 2020 Jun 19;14(5):617-623. (PMID: 31867632) Aliment Pharmacol Ther. 2002 Jul;16(7):1225-32. (PMID: 12144571) J Crohns Colitis. 2017 Aug 01;11(8):954-962. (PMID: 28333358) Cancer Discov. 2015 Dec;5(12):1328-43. (PMID: 26408659) Gut. 2000 Oct;47(4):514-9. (PMID: 10986211) Cancers (Basel). 2023 Jan 25;15(3):. (PMID: 36765708) JAMA. 2014 Jun 18;311(23):2406-13. (PMID: 24938563) Cancer. 2001 Feb 15;91(4):854-62. (PMID: 11241255) Cancer. 1985 Dec 15;56(12):2914-21. (PMID: 4052961) Res Synth Methods. 2021 Jan;12(1):55-61. (PMID: 32336025) BMJ. 2016 Oct 12;355:i4919. (PMID: 27733354) JAMA. 2017 Nov 07;318(17):1679-1686. (PMID: 29114832) J Crohns Colitis. 2015 Nov;9(11):945-65. (PMID: 26294789) Am J Gastroenterol. 2000 Sep;95(9):2308-12. (PMID: 11007233) Am J Gastroenterol. 2011 Dec;106(12):2146-53. (PMID: 22031357) World J Gastroenterol. 2016 Dec 14;22(46):10103-10117. (PMID: 28028358) Aliment Pharmacol Ther. 2020 Oct;52(8):1289-1297. (PMID: 32840893) Int J Cancer. 2016 Sep 15;139(6):1270-80. (PMID: 27170593) Digestion. 2016;94(1):1-8. (PMID: 27318857) Dig Dis Sci. 2011 May;56(5):1489-95. (PMID: 20953706) J Crohns Colitis. 2018 Aug 29;12(9):1042-1052. (PMID: 29762681) Am J Pathol. 1995 Jul;147(1):217-22. (PMID: 7604881) Cancer Res. 1982 Jan;42(1):331-34. (PMID: 7053860) Am J Gastroenterol. 2010 Jul;105(7):1604-9. (PMID: 20104215) Clin Med Insights Oncol. 2021 Jun 17;15:11795549211024197. (PMID: 34211309) Front Cell Infect Microbiol. 2022 Feb 22;12:733992. (PMID: 35273921) Gut. 2005 Aug;54(8):1121-5. (PMID: 16009685) Clin Gastroenterol Hepatol. 2015 May;13(5):847-58.e4; quiz e48-50. (PMID: 24879926) Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93. (PMID: 14984375) J Pathol. 2000 Jul;191(3):333-40. (PMID: 10878557) Nat Rev Gastroenterol Hepatol. 2017 May;14(5):269-278. (PMID: 28144028) Gastroenterology. 2013 Nov;145(5):1007-1015.e3. (PMID: 23891975) J Gastroenterol Hepatol. 2022 Aug;37(8):1544-1553. (PMID: 35501287) Nat Rev Gastroenterol Hepatol. 2023 Feb;20(2):79-80. (PMID: 36635556) Cancer Causes Control. 2000 Feb;11(2):145-50. (PMID: 10710198) Arq Gastroenterol. 2013 Apr;50(2):123-9. (PMID: 23903622) Gastroenterology. 2000 Sep;119(3):647-53. (PMID: 10982757) Cancer Res. 1977 Oct;37(10):3533-6. (PMID: 908005) |
| فهرسة مساهمة: | Keywords: biologic agents; inflammatory bowel disease; lymphoma; proctocolectomy; ulcerative colitis |
| تواريخ الأحداث: | Date Created: 20230519 Latest Revision: 20230522 |
| رمز التحديث: | 20230522 |
| مُعرف محوري في PubMed: | PMC10188968 |
| DOI: | 10.3389/fmed.2023.1172634 |
| PMID: | 37206474 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2296-858X |
|---|---|
| DOI: | 10.3389/fmed.2023.1172634 |